Form 4: Brainstorm Cell Therapeutics Executive Acquires Shares and Options

EVP and COO Hartoun Hartounian of Brainstorm Cell Therapeutics acquires 30,000 shares of common stock and options to purchase 60,000 shares.

Summary

• On June 24, 2024, Hartoun Hartounian, EVP and Chief Operating Officer of Brainstorm Cell Therapeutics Inc., acquired 30,000 shares of common stock and options to purchase 60,000 shares.
• The 30,000 shares were awarded as restricted stock units (RSUs) under the company's 2014 Stock Incentive Plan and will vest on June 24, 2025, contingent upon continued employment.
• The option to purchase 60,000 shares at an exercise price of $0.38 also vests over time, with 25% vesting on June 24, 2025, and the remainder vesting in equal quarterly installments over the following three years, also contingent upon continued employment.
• Following the transaction, Hartounian directly owns 30,000 shares and options to purchase 60,000 shares.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it reflects an executive's increased stake in the company, aligning their interests with shareholders. However, it's a routine transaction and doesn't necessarily indicate a major shift in the company's prospects.

Positives

• The acquisition of shares and options by a key executive could be seen as a positive sign, indicating confidence in the company's future prospects.
• The vesting schedules for both the RSUs and options incentivize the executive to remain with the company.

Future Outlook

The vesting of the RSUs and stock options is contingent upon Hartounian's continued employment with Brainstorm Cell Therapeutics.

Industry Context

Executive compensation in the biotech industry often includes stock options and restricted stock units to align management's interests with those of shareholders and incentivize long-term value creation.

Stakeholder Impact

• The transaction could have a slightly positive impact on shareholders as it aligns the executive's interests with theirs.
• Employees may view the executive's increased stake as a sign of confidence in the company's future.

Key Dates

Keywords

Brainstorm Cell Therapeutics, Hartoun Hartounian, stock options, restricted stock units, BCLI, executive compensation, Form 4, insider trading